#USA #ADRX-0706 #Nectin-4 #Chicago, IL #Adcentrx Therapeutics

Adcentrx Therapeutics to Present Clinical Data at ASCO 2025

Adcentrx Therapeutics, a trailblazer in the biotechnology realm, is slated to showcase the first clinical data for its innovative drug, ADRX-0706, at the forthcoming American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for May 30 to June 3, 2025, in Chicago, Illinois. As a clinical-stage company, Adcentrx is dedicated to redefining antibody-drug conjugate (ADC) therapies, particularly for cancer and other critical health conditions.

Overview of ADRX-0706

ADRX-0706 is a next-generation Nectin-4 ADC, which promises to address substantial unmet medical needs for cancer patients with limited treatment options. During the ASCO conference, Adcentrx will present interim results from its Phase 1a dose escalation study. This foundational part of the clinical trial has been designed to assess the initial safety and tolerability of ADRX-0706 in individuals suffering from advanced solid tumors.

Key Clinical Findings

Preliminary data from the Phase 1a trial indicates a strong proof of concept for this novel platform, notably highlighting ADRX-0706's considerable potential as a best-in-class therapy. The findings reveal a distinctive safety and pharmacokinetic profile, featuring a remarkably lower frequency of significant adverse events, such as peripheral neuropathy, which can often accompany other ADC treatments. Furthermore, early signals of efficacy have emerged across varying dose levels and tumor types, underscoring the therapeutic advantages of Adcentrx's proprietary i-Conjugation technology combined with its innovative payload, AP052.

Study Trials and Design

The ongoing clinical investigation is comprised of two main parts: Phase 1a and Phase 1b. The Phase 1a dose escalation has been essential in determining the appropriate dosage for further studies, focusing on patients with specific advanced cancers, including those of the urothelial, triple-negative breast, and cervical types. The poster presentation at ASCO will detail the preliminary results, carrying the unique abstract number 3018. It is set against the backdrop of another informative session,